期刊文献+

二硫键在药物研发中的应用及其研究进展 被引量:2

Application and research progress of disulfide bonds in drug development
原文传递
导出
摘要 二硫键作为重要的化学基团在天然产物结构中广泛存在,一些含有二硫键的化合物表现出很好的生物活性,包括抗肿瘤、抗氧化、抗菌和酶抑制活性等。近年来,基于二硫键的氧化还原响应性药物传递系统特异性的释放抗肿瘤药物更是成为研究热点。本文主要介绍含有二硫键的单体药物以及药物-载体缀合物的研究进展,并概述其化学结构、药理作用以及二硫键的生物化学功能。 Disulfide bonds are widely distributed in natural products as important chemical groups. Some com- pounds containing disulfide bonds exhibit good biological activities, including anti-tumor, anti-oxidation, en- zyme inhibition and antibacterial activities. In recent years,redox-responsive drug delivery systems that speci- fically release drugs based on disulfide bonds in tumor cells have become a research highlight. In this paper, the development of drugs and the drug-cartier conjugates containing disulfide bonds were reviewed and the chemical structures, pharmacological properties and biochemical functions of disulfide bonds were summa- rized.
出处 《中国药物化学杂志》 CAS CSCD 北大核心 2018年第1期71-76,86,共7页 Chinese Journal of Medicinal Chemistry
基金 国家自然科学基金项目(21472247)
关键词 二硫键 二硫化物 药物传递系统 disulfide bond disulfides drug delivery system
  • 相关文献

参考文献4

二级参考文献22

  • 1徐铮奎.-[J].中国保健食品,1999,12(3):41-42.
  • 2CRISCIONE VD, WEINSTOCK MA. Incidence of cutaneous Tcell lymphoma in the United States, 1973 - 2002 [ J]. Arch Dermatol,2007,143 (7) :854 - 859.
  • 3FURUMAI R, MATSUYAMA A, KOBASHI N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone dcacetylases [ J ]. Cancer Res,2002,62 ( 17 ) :4916 - 4921.
  • 4LANSIGAN F, FOSS FM. Current and emerging treatmentstrategies for cutaneous T-cell lymphoma [ J]. Drugs, 2010,70 (3) :273 -286.
  • 5GRANT C, RAHMAN F, PIEKARZ R, et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors [ J ]. Expert Rev Anticancer Ther, 2010, 10 (7) :997 - 1008.
  • 6SANDOR V, BAKKE S, ROBERT W,et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide ( FR901228, NSC630176), in patients with refractory neoplasms [ J ]. Clin Cancer Res,2002,8 (3) :718 - 728.
  • 7PIEKARZ RL,FRYE R,TURNER M,et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma[ J ]. J Clin Oncol, 2009,27(32) :5410 -5417.
  • 8WOO S, GARDNER ER,CHEN X,et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma [ J]. Clin Cancer Res, 2009,15(4) :1496 - 1503.
  • 9FOULADI M, FURMAN WL, CHIN T,et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report [ J ]. J Clin Oncol, 2006,24 (22) :3678 -3685.
  • 10SHIRAGA T,TOZUKA Z, ISHIMURA R,et al. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes [J]. Biol Pharm Bull,2005,28(1):124-129.

共引文献29

同被引文献10

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部